Indegene Limited (NSE:INDGN)
India · Delayed Price · Currency is INR | Market Cap | 146.95B +17.0% |
| Revenue (ttm) | 41.31B +35.8% |
| Net Income | 4.11B -7.8% |
| EPS | 17.01 -8.0% |
| Shares Out | 240.90M |
| PE Ratio | 35.86 |
| Forward PE | 24.76 |
| Dividend | 2.25 (0.37%) |
| Ex-Dividend Date | Jul 31, 2026 |
| Volume | 226,295 |
| Open | 611.00 |
| Previous Close | 613.35 |
| Day's Range | 600.00 - 618.00 |
| 52-Week Range | 414.00 - 638.00 |
| Beta | 0.68 |
| Analysts | Strong Buy |
| Price Target | 696.63 (+14.2%) |
| Earnings Date | Oct 29, 2026 |
About Indegene
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, North America, and internationally. It operates through Enterprise Medical Solutions, Enterprise Commercial Solutions, and Other segments. The company provides AI-embedded commercialization services for biopharmaceutical, emerging biotech, and medical devices companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technolog... [Read more]
Financial Performance
In fiscal year 2026, Indegene's revenue was 35.11 billion, an increase of 23.64% compared to the previous year's 28.39 billion. Earnings were 4.01 billion, a decrease of -1.38%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for INDGN stock is "Strong Buy." The 12-month stock price target is ₹696.63, which is an increase of 14.20% from the latest price.
News
Indegene Transcript: Q2 26/27
Q2 revenue rose 39.5% YoY in INR, while EBITDA margin was 16.7% after wage increases and lower investment yields. Management expects stronger H2 and targets 19%+ quarterly EBITDA margin by Q4, supported by productivity and contract ramp-ups.
Indegene Quarterly report: Q2 2027
Indegene has published its Q2 2027 quarterly earnings report on October 29, 2026.
Indegene Slides: Q2 2027
Indegene has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on October 29, 2026.
Indegene Transcript: Q1 26/27
Q1 FY 2027 saw 39.7% year-on-year revenue growth and strong client diversification, with margins expected to recover to 19%-20% by Q4 as large outcome-based deals begin contributing. Strategic investments in AI and technology underpin confidence in sustained growth.
Indegene Quarterly report: Q1 2027
Indegene has published its Q1 2027 quarterly earnings report on July 30, 2026.
Indegene Slides: Q1 2027
Indegene has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 30, 2026.
Indegene Slides: Investor presentation
Indegene has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Indegene Transcript: Q4 25/26
Record revenue and EBITDA growth driven by deepening customer relationships, GenAI-led innovation, and strategic acquisitions. Strong cash flows and improved margins expected as investments are absorbed, with a robust pipeline and industry tailwinds supporting multi-year growth.
Indegene Quarterly report: Q4 2026
Indegene has published its Q4 2026 quarterly earnings report on April 29, 2026.
Indegene Slides: Q4 2026
Indegene has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 29, 2026.
Indegene Annual report: Q4 2026
Indegene has published its Q4 2026 annual report on April 29, 2026.
Indegene Transcript: Q3 25/26
Q3 FY2026 delivered 30.8% year-on-year revenue growth and 18.5% adjusted EBITDA margin, driven by large AI-enabled deal wins and successful BioPharm integration. Management expects margins to improve and strong cash flows to continue as synergies materialize.
Indegene Quarterly report: Q3 2026
Indegene has published its Q3 2026 quarterly earnings report on January 29, 2026.
Indegene Slides: Q3 2026
Indegene has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 29, 2026.